Human CMV infection is a frequent complication after HSC in children with remarkable morbidity and mortality. Antiviral drugs are relatively efficient but have numerous side effects. They are used as prophylactic, pre-emptive or therapeutic medicines. It is still a matter of debate which option is the best strategy. No uniform procedure has emerged regarding these three options, and new immunologic tools have raised more questions for physicians. To assess the current practice in the management of CMV infection, we sent a questionnaire to the EBMT centers performing hematopoietic SCT (HSCT) in children. Fifty-six out of 196 responded to the questionnaire (28.5%). Quantitative PCR was the most common monitoring tool (44/56). Only 4/56 centers use the pp65 antigenemia alone. All centers used pre-emptive strategy (56/56). 21/56 centers also used prophylactic measures, 13/21 after analysis of donor/receptor serologic status. Ganciclovir was the most common first-line agent for CMV disease (55/56). The most common dose and duration for induction treatment were 5 mg/kg bid (47/55) for 14 days (20/55). There is no uniform procedure for researching resistance strain, antiviral second-line therapy or cell therapy. A harmonization process should enable sound prospective trials to improve prevention, control and cure of CMV disease in children and adolescents.
INTRODUCTION
Despite improvements achieved in the allogeneic hematopoietic SCT(HSCT setting, human CMV infection still remains a relevant complication both in adults and children. [1] [2] [3] [4] CMV infection in transplant recipients can cause direct organ lesion and indirect effects with a potential role of CMV immunomodulatory abilities, particularly in GVHD occurrence or re-flare. 2, [5] [6] [7] [8] To prevent and control CMV infection, clinicians have to define procedures for monitoring. Specific and sensitive tests are available-that is, pp65 antigenemia and real-time PCR. Both methods are established tools but there is no consensus on biological monitoring schedules. [9] [10] [11] [12] Different biological and clinical situations have to be distinguished: serological status giving evidence of previous CMV contact; CMV reactivation corresponding to detection of either viral DNA or antigen in blood sample; CMV infection in which DNA or antigen is detectable in association with fever; and CMV disease when clinical symptoms, organ involvement and virus detection are associated. 4, 5 Two strategies are applied to prevent CMV infection: prophylaxis strategy that exposes all patients to antiviral drugs, regardless of screening tests for CMV replication or pre-emptive therapy, which initiates antiviral treatment based on screening test results. [13] [14] [15] [16] There is no evidence that one strategy is superior to the other. 17 Different antiviral drugs are used; however, none is licensed for children. These drugs are active on CMV replication but not on latency, and they expose patients to toxicities and to emergence of resistant strains. [18] [19] [20] [21] [22] The lack of pharmacological studies, particularly in children, and the lack of clinical trials testing these antiviral drugs and the probable benefit/risk ratio make clinician's choice difficult. 23 It is well known that beside anti-CMV, pharmaceutical cells are necessary to prevent or control CMV infection and/or reactivation. Hence, new immunological tools and adoptive cell therapy have raised new options 10, [24] [25] [26] [27] to improve CMV infection detection and outcomes.
To our knowledge, no survey has focused on CMV infection management in pediatric transplant centers so far. To assess the current situation, we sent a questionnaire on CMV infection management to all EBMT centers performing allogeneic HSCT in children and adolescents.
MATERIALS AND METHODS
A 30-item questionnaire regarding CMV infection management was sent to EBMT centers performing pediatric HSCT. 
RESULTS

From 12
December 2009 to 01 April 2010, 196 centers received the questionnaire and 56 EBMT centers (28. 5%) from 26 countries completed the questionnaire and sent it back. All responding centers performed pediatric transplantation either exclusively or associated with adult HSCT. Most of these centers performed both related and unrelated HSCT, including for some of them alternative HSCT from partially matched unrelated cord blood or haplo-identical HSCT. According to EBMT 2010 annual activity report, all together these 56 centers performed about 2150 allogeneic HSCT a year-that is, 17.5% of all Promise-database registered allogeneic HSCT and around 45% of pediatric activity. 28 The median annual activity for responding centers is 30 allogeneic HSCT a year (range: 1-142).
As indicated above, except for some questions (number specified in text), all results are given out of the 56 responding centers. However, as multiple responses have been allowed, the total may be 456 for some results.
Biological monitoring
Quantitative PCR was performed in 44 centers, qualitative (that is, no quantitative PCR) PCR in 17 and pp65 antigenemia alone in 4. Seventeen out of 56 programs used both PCR and pp65 antigenemia, and 15 programs used both quantitative and qualitative PCR. Biological material used for viral replication tests was whole blood in 38 centers, plasma in 22 centers or separated cells in 7 centers. In 51 centers, 91% results were expressed as CMV DNA copies/mL and in 12 as qualitative response-that is, positive or negative. Twelve out of 56 centers validated their results in copies of DNA of CMV reported to be X cells. Nine centers had precise X values: 10 000 (1 center), 20 000 (1 center), 100 000 (5 centers), 200 000 (1 center), 250 000 (1 center).
Biological monitoring of viral replication starts after day þ 7 following the graft in 36 programs, in which 13 centers start monitoring after engraftment and 5 when leukocyte count is above 500/mL. This monitoring was performed once a week in 34 centers and twice a week in 18 centers. Two out of 56 centers monitor CMV three times per week.
Monitoring was carried out until discontinuation of immunosuppression in 30 centers, up to immune reconstitution in 29 centers (without given precisions about definition of immune reconstitution) and up to day þ 100 after HSCT in 20 centers. Fourteen centers modulated their monitoring schedule regarding stem cell source and donor type.
Positive threshold for real-time PCR was 1000 copies/mL in 33/ 44 centers and 5000 copies/mL in 4/44 centers. Positive threshold was 1 cell/200 000 in 8/21 centers and 2 cells/200 000 in 6/21 centers using pp65 antigenemia (threshold has been not indicated by the seven remaining centers).
Prophylactic strategy A prophylaxis approach was used in 21 programs. Among these programs, 13/21 choose this option after the analysis of the serological donor/recipient CMV status. Antivirals for this indication were aciclovir (Glaxo-SmithKline, London, UK) for 9/21, ganciclovir (Roche, Basel, Switzerland) for 8/21 and foscarnet (Clinigen Healthcare, Burton-on-Trent, UK) for 1/21; three centers did not specify the drug used.
Pre-emptive strategy Pre-emptive therapy was used by all the responding centers. Treatment of CMV infection started after either one positive or two positive results in 26 and 27 centers, respectively; three centers used both signals. The most common first-line pre-emptive therapy was Ganciclovir (55 programs, including before engraftment in 22). Foscarnet was used in 19 centers. Valganciclovir was used in 18 centers, including 3/18 before the occurrence of engraftment. Finally, four centers used Cidofovir.
Schedule and drug doses Ganciclovir. The dose of induction therapy is 5 mg/kg per 12 h (47/55, one center did not specify) during 14 days in 20 out of 47 responding centers to this question. Twenty centers shortened this treatment when virus became undetectable. Thirty-nine (71%) centers used a maintenance therapy. Among them, 32 gave the dose of 5 mg/kg once a day either for 14 days (20 centers) or 5 days a week for 2 weeks (10 centers). Two centers performed Ganciclovir plasma-level monitoring in order to adapt dosage.
Foscarnet. This antiviral drug is used in 45 centers. The dose of induction treatment is 90 mg/kg twice daily in 24 centers (53%), 60 mg/kg twice daily in 15 centers (33%) and 60 mg/kg per 8 h in 6 centers (14%). Induction treatment is systematically administered during 14 days in 34 centers, whereas 11 centers shorten this treatment if virus is no longer detectable. Thirty centers out of 45 use maintenance therapy. Dose of maintenance therapy is either 60 or 90 mg/kg once a day in 8 and 22 centers, respectively. It is pursued every day for 14 days in 12/30 centers and 5 days a week during 2 weeks in 10/30 centers; eight centers did not specify. 
Second-line therapy
In the case of treatment failure, change of antivirals was the option in 51 centers. If Ganciclovir was the first-line drug, it could be switched for Forscarnet in 49 centers or for Cidofovir in 5. If Foscarnet was the first-line drug, it could be switched for Ganciclovir in 13 centers or for Cidofovir in 9.
Association of two antiviral drugs is an option in 21 centers: Ganciclovir-Foscarnet association is used in 18 centers, Ganciclovir-Cidofovir in 5 centers and Foscarnet-Cidofovir in 1 center.
Resistant strains
In 23 centers, the presence of a drug-resistant CMV mutant was checked in case of treatment failure: in 9 centers by restriction CMV in pediatric transplantation: results of an EBMT survey T Bontant et al analysis and in 14 centers by sequencing. Delays of result validation fluctuate from 3 days to 6 weeks.
Cell therapy This treatment technique was performed in 11 centers. Indications were as follows: CMV disease and treatment failure in 10, delay of immune reconstitution in 4, development or co-existence of active GVHD in three programs and antiviral drug toxicity in one center.
DISCUSSION
This EBMT survey demonstrates that each responding center has its own management protocol for CMV infection. In this survey, we did not distinguish management between reactivation/infection and disease. This situation is probably because of the absence of sufficient and comprehensive data leading to stringent treatment protocols and underlines the need for both, academic and industry studies. Many centers have developed protocols, generally on previous experience or local conditions (laboratory equipment, drug availability and cost).
For example, and as mentioned below, biological monitoring of viral replication, biological tests and their schedules are probably chosen in collaboration with laboratories. The most frequently used technique is real-time PCR (41/56). This technique is easy to perform for laboratories, as it can be performed in batches on stored samples and can be automated. While pp65 antigenemia needs a 6-hours manual technique to be performed on fresh blood sample specimen, requires subjective interpretation and is not reliable in neutropenic patients. 29, 30 However, Marchetti et al. 31 demonstrated that RT-PCR is a reliable diagnostic tool and that it can be more effective than pp65-based assays in monitoring CMV infection progression and in guiding therapy in immunocompromised patients. 31 Procedure differences between centers exist also in the performance of real-time PCR: in the sample type (whole-blood sample (38/56), plasma (22/56) or separated cells (7/56)), in the description of the results (CMV DNA copies/mL (12/56), copies of CMV DNA reported to X cells (12/56)), in the time from which monitoring starts (36/56 in the first week following the graft, 13/56 at engraftment, 5/56 leukocyte count above 500/mL) and the testing frequency (once a week in 34/56 centers but differs in other centers). Another issue is that values obtained with different real-time PCR protocols are not comparable. An international standard reference for amplification of CMV DNA should help to standardize assays of real-time PCR protocol for CMV infection diagnosis. 32 As immunological reconstitution differs between patients according to stem cell source, donor/recipient HLA match level, the intensity of conditioning regimen and both prophylaxis and treatment of GVHD common standards are not appropriate for the different conditions. In the near future, integration of immunological parameter monitoring in the algorithm for CMV monitoring and therapy should change our approach by detecting patients who could spontaneously control CMV infection. 26 All centers that answered to this survey use pre-emptive strategy, including those using prophylactic strategy also for either all or only the high-risk patients. The definition of high-risk patients differs between the centers, either only seronegative donor/seropositive recipient or all D/R pair with at least one positive member. Pre-emptive strategy was described for the first time by Boeckh et al. in 1996 and was rapidly and widely used, 34 In this paper, Boeckh et al. 34 reported a randomized double-blind study on 226 allogeneic HSCT recipients who received either prophylactic or pre-emptive ganciclovir. They observed more CMV diseases by day 100 (but not by day 180) in pre-emptive arm than in the prophylactic arm and more invasive fungal infection in prophylactic arm than in the preventive one. Finally, OS was identical in both arms. In 2011 ASH education program, Boekh indicated that both strategies still remained useful. 24 However, there was no available study, either in adult or pediatric population, allowing clear recommendations for choosing either prophylactic or pre-emptive strategy. By definition, prophylactic strategy exposes all patients to antiviral drugs and to side effects. [13] [14] [15] [16] It also could be possible-but not demonstratedthat this strategy may facilitate the emergence of resistant viral strains. On the other hand, some studies report an excess of late CMV reactivation as compared with prophylactic strategy and may be more late CMV diseases. For second-line therapy, analysis of results show that definition of treatment failure is not so clear and that 23/56 centers seek for resistant strain in this situation. There is no common approach about antiviral switch or association of two molecules. 10 This last option is chosen in 22/56 programs.
Differences regarding toxic profile-for example, renal toxicity for foscarnet and bone marrow toxicity for ganciclovir-limited antiviral activity (primary or secondary viral strain resistance), added to the absolute lack of trials studying pharmacokinetics of these different compounds or comparing the results obtained with different drugs and different schedules could explain the wide heterogeneity we report here.
We did not ask any question regarding the use of either polyvalent or CMV-specific IgIV in the center strategies. However, none of the centers specified to use it in free comment space included in the questionnaire.
Cell therapy-a very recent treatment modality-seems to be used in 11/56 of the responding centers. To date, cell therapy techniques are difficult to perform, in terms of logistics for the production of virus-specific T cells. A new technique, described by Feuchtinger et al. 25 has been described and used in a clinical trial. The development of multi-virus-specific T cells associated to the availability of CTL from third-party donors and/or from banks could modify the habits of the centers in the future. 35 
CONCLUSION
We conclude in this survey report that CMV monitoring, prophylaxis and treatment in children are still an 'individualized' or a 'center' process. Our data may provide a basis for the establishment of an algorithm to manage CMV infection in different pediatric transplantation scenarios. This survey attests that management of this infection varies widely between centers as clinicians have many choices to make with few rational data. International standards for human CMV for nucleic acid amplification techniques are in development and will probably help to reach consensus on biologic monitoring and positive threshold. More studies are needed to help in finding the appropriate schedule and dosage in pediatric transplantation, in both first-and second-line therapies. The current development of cell therapy has already changed CMV chemorefractory disease management. New drugs are under development and we have to strongly argue with pharmaceutical companies to convince them of the huge importance of pediatric investigation plans.
Propositions
Response analysis may allow us to propose the basic rules for human CMV infection management in pediatric allogeneic HSCT.
Monitoring should be performed with quantitative PCR, at least once a week. We suggest that 14 days of Ganciclovir at 5 mg/kg/bid or Foscarnet at 90 mg/kg/bid should be the first-line treatment of CMV infection in an pre-emptive strategy. Cidofovir may be an option only for second-line treatment. Data are not sufficient to propose the dosage for Cidofovir. Specific immunotherapy using anti-CMV CTL has to be considered as the second-or the third-line therapy. A schedule for maintenance therapy cannot be proposed either. This survey was not about finding a consensus; however, these propositions are the reflection of the centers' most shared attitude.
